Skip to main content
. 2012 Dec;47(6):729–737. doi: 10.1165/rcmb.2012-0057OC

Figure 5.

Figure 5.

Effect of PGE2 pretreatment (24 h) on PGE2-mediated inhibition of chemotaxis in lung fibroblasts obtained from patients with chronic obstructive pulmonary disease (COPD) and healthy control subjects. (a-1) PGE2-mediated chemotaxis of pooled control (n = 8) fibroblast strains pretreated in the presence or absence PGE2 for 24 hours. (a-2) PGE2-mediated chemotaxis of pooled COPD (n = 12) fibroblast strains pretreated in the presence or absence PGE2 for 24 hours. (b) Schema depicting cAMP saturation of PDE4 enzymes after increased agonist stimulation. (c) Schema of global activity of PGE2 activated PDE4 enzymes on multiple cAMP-coupled pathways. ****P < 0.0001; ***P < 0.001; **P < 0.01; *P < 0.05. Bars are means ± SEM. AC = adenylyl cyclase; B2AR = β2 adrenergic receptor; Gs = Gαs G protein; IPr = prostacyclin receptor.